Jan 2, 2022
MediSieve Named 2021 Champion of Super Connect for Good Competition
MediSieve was selected as the Overall Champion of the 2021 Super Connect for Good Competition organised by Empact Ventures and Hays.
The Super Connect for Good Competition seeks to discover and super connect the best emerging tech startups and scale-ups creating positive social impact to enhance people’s lives through technology. In 2021, the Super Connect for Good welcomed applications from Tech for Good startups & scale-ups from across the UK, Ireland and Europe. The streams include: Applications are welcome in AI for Good, EdTech, HealthTech, MedTech, FinTech for Good & CleanTech, Pre-Seed Challenge, in partnership with Microsoft and the Industry Challenge set by Seimens Mobility. 10 startups are shortlisted from each stream and are invited to participate at the Top 100 Innovation Showcase from across the UK, Ireland & Europe as well as are featured in the European Tech for Good Report. MediSieve has been awarded as an Overall Champion from the 100 shortlisted startups.
Upon winning the competition MediSieve's founder and CEO George Frodsham gave an interview to Top Business Tech. George explained the technology of Magnetic Haemofiltration and stated that: "the magic happens outside of the body, within this extracorporeal loop while the blood is being circulated through it."
George also talked about company's response to Covid-19. The top priority has been the safety of the employees and then the team focused on how MediSieve's technology can be used to tackle the pandemic. The company has developed 3D printing ear guards, which were shipped to London hospitals, which prevent the elastics form the masks causing pain to the ears.
Super Connect for Good Competition has allowed MediSieve to connect with a variety of resources which would not be accessible otherwise. The publicity has also provided a boost in terms of company’s social media, increasing awareness about the technology MediSieve is making.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: